Adage Capital Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Adage Capital Partners’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100,000	Closed	-$4.77M	–	1180
2021 Q4	$4.77M	Sell	100,000 -14,822	-13%	-$663K	0.01%	820
2021 Q3	$7.63M	Sell	114,822 -85,178	-43%	-$6.07M	0.02%	774
2021 Q2	$15.6M	Buy	200,000 +100,000	+100%	+$7.39M	0.03%	555
2021 Q1	$9.46M	Sell	100,000 -75,000	-43%	-$8.92M	0.02%	701
2020 Q4	$21.3M	Sell	175,000 -25,000	-13%	-$2.74M	0.05%	403
2020 Q3	$17.5M	Buy	200,000 +25,000	+14%	+$1.74M	0.04%	413
2020 Q2	$11.3M	Buy	175,000 +50,000	+40%	+$2.88M	0.03%	507
2020 Q1	$5.58M	Buy	125,000 +100,000	+400%	+$5.31M	0.02%	561
2019 Q4	$1.56M	Sell	25,000 -175,000	-88%	-$8.33M	﹤0.01%	666
2019 Q3	$7.52M	Hold	200,000	–	–	0.02%	575
2019 Q2	$8.14M	Buy	+200,000	New	+$7.13M	0.02%	554

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Adage Capital Partners's TPTX Position: Q1 2022 in Review

Adage Capital Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 100,000 shares — an estimated $4.77M sold.

Adage Capital Partners first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $21.3M in Q4 2020. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

Adage Capital Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Adage Capital Partners sold 100,000 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $4.77M.
Adage Capital Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
Adage Capital Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $21.3M in Q4 2020.
155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Adage Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.